Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To proof the superiority of an 8-week rectal treatment with once-daily 2 mg budesonide versus
placebo for the prevention of acute radiation proctitis, and to evaluate the occurrence of
chronic radiation proctitis 1 year after start of radiation therapy.